Last month we featured Brad Novak's story, Build a Better Future for NET Patients, and because it touched so many, we wanted to share it again for anyone who may have missed it. Brad was a beloved family man, expert custom home builder and cherished member of the Aurora, CO community. His wife Kathy and their children continue to raise money for NETRF in Brad's memory. Please join the Novak family and the NET community with your gift this season. Every gift is important and provides funding for new and critical NET research. (See Brad's story here.)
We're making it even easier for you to make a donation during our year-end appeal right from your phone! Help us Build a Better Future for NET Patients. Just scan the QR code below with your phone camera and you'll be redirected to our donation page.
NETRF has experienced a significant increase in tribute giving this year, and while this increase is both heartwarming and bittersweet for us, we are grateful that so many people choose to honor their loved ones with a gift to NETRF. We have received almost $400,000 in tribute giving, and have surpassed the number of tribute gifts given in 2020.
Memorial gifts to NETRF allow you to remember someone special, celebrate the life they lived and the impact they made, while supporting innovative research to discover improved treatments and cures for neuroendocrine cancers.
Thank you for including NETRF in your giving plans.
We want to thank all the speakers and attendees who participated in our 2021 KNOW YOUR NETs Virtual Patient Education Conference on November 7. There have been almost 700 views of the conference on our website and YouTube channel. If you missed the conference or wish to see any of the presentations again, click here. NETRF thanks all our sponsors for their support of this successful conference.
14th Annual NETRF Research Symposium Recap
The fourteenth annual NETRF Research Symposium successfully concluded last month with over 300 registered virtual attendees participating from around the globe for the second year in a row. The meeting included nearly 60 talks and posters representing the cutting edge of NET research as investigators reported their latest data and discoveries to share and discuss with colleagues. This year posters were available for viewing over the three days preceding the two-day meeting, resulting in over 300 poster views and ample time for discussions. Over 95% of registrants attended the two-days of talks and live discussions while the recorded talks and posters were viewed by over 100 more attendees over the following week. Read more here.
Dr. Chrissie Thirlwell is new NETRF Board of Scientific Advisors
Co-Chair
Chrissie Thirlwell, MD, PhD, the Mireille Gillings Professor of Cancer Genomics at the University of Exeter Medical School will assume the role of BOSA co-chair in January of 2022. She succeeds Dr. George Fisher. Dr. Thirlwell is internationally renowned for advancing NET research, the clinical management of NETs and the integrated genomic analysis of cancer. Read more here.
Digital analysis to predict NET tumor characeristics
Dr. Michelle Kang Kim, a gastroenterologist and NET specialist at the Icahn School of Medicine at Mount Sinai in New York, is working to develop a diagnostic tool to help predict patient outcomes for pancreatic and midgut NETs. Dr. Kim received a NETRF pilot award to test the use of digital image analysis to identify and measure predictive tumor characteristics. Hear more from Dr. Kim in this video.
New Clinical Trial Explores Use of Anti-Cancer Drug
A phase 1a/1b clinical trial is being conducted in patients who have poorly differentiated neuroendocrine cancer, advanced small cell lung cancer or pancreatic cancer. Satya Das, MD, MSCI, at Vanderbilt University Medical Center serves as principal investigator of the study, which is sponsored by the National Cancer Institute. Read more here.
Mailman appointed to
NRC Advisory Committee
Congratulations to NETRF Board member and patient advocate Josh Mailman for his recent appointment as Patients’ Rights Advocate on the Advisory Committee on the Medical Uses of Isotopes. In this role, he provides input to National Regulatory Commission staff and ensures patients’ rights are represented during the development and implementation of policies governing medical uses of radioactive material in diagnosis and therapy. Josh also serves as President of NorCal CarciNET Community and is recognized for his work in the neuroendocrine cancer and nuclear medicine communities.
Special thanks to Advanced Accelerator Applications,
a Novartis Company,
for their sponsorship of NETRF's November eUpdate.
The mission of the Neuroendocrine Tumor Research Foundation is to fund research to discover cures and more effective treatments for carcinoid, pancreatic, and related neuroendocrine cancers.
NETRF is a 501(c)(3) organization. All contributions are tax-deductible to the extent allowed by law. To learn more,
view our Audited Financial Statements and IRS Form 990.
Share this email:
Manage your preferences | Opt out using TrueRemove™
Got this as a forward? Sign up to receive our future emails.
View this email online.
